Karen Uhlmann
Oprichter bij OMEICOS Therapeutics GmbH
Actieve functies van Karen Uhlmann
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
OMEICOS Therapeutics GmbH
 OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Operationeel Directeur | 01-01-2013 | - |
| Oprichter | 01-01-2013 | - | |
| Algemeen Adviseur | 01-01-2013 | - |
Loopbaan van Karen Uhlmann
Opleiding van Karen Uhlmann
| Freie Universität Berlin | Graduate Degree |
| Humboldt-Universität zu Berlin | Doctorate Degree |
Statistieken
Internationaal
| Duitsland | 4 |
Operationeel
| Chief Operating Officer | 1 |
| Founder | 1 |
| General Counsel | 1 |
Sectoraal
| Consumer Services | 3 |
| Health Technology | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
OMEICOS Therapeutics GmbH
OMEICOS Therapeutics GmbH BiotechnologyHealth Technology OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany. | Health Technology |
- Beurs
- Insiders
- Karen Uhlmann
- Ervaring
